Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Ascendis Pharma A (ASND) over the last 7 years, with Q4 2025 value amounting to -$11.1 million.

  • Ascendis Pharma A's Change in Receivables rose 9166.34% to -$11.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.6 million, marking a year-over-year increase of 10678.68%. This contributed to the annual value of $17.6 million for FY2025, which is 11389.9% up from last year.
  • Per Ascendis Pharma A's latest filing, its Change in Receivables stood at -$11.1 million for Q4 2025, which was up 9166.34% from -$29.1 million recorded in Q3 2025.
  • Ascendis Pharma A's 5-year Change in Receivables high stood at $103.1 million for Q1 2025, and its period low was -$133.4 million during Q4 2024.
  • In the last 5 years, Ascendis Pharma A's Change in Receivables had a median value of -$5.9 million in 2021 and averaged -$8.7 million.
  • Per our database at Business Quant, Ascendis Pharma A's Change in Receivables surged by 284089.95% in 2021 and then plummeted by 378647.78% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Change in Receivables stood at $3.0 million in 2021, then plummeted by 284.63% to -$5.6 million in 2022, then tumbled by 64.71% to -$9.2 million in 2023, then tumbled by 1354.25% to -$133.4 million in 2024, then surged by 91.66% to -$11.1 million in 2025.
  • Its last three reported values are -$11.1 million in Q4 2025, -$29.1 million for Q3 2025, and -$54.3 million during Q2 2025.